Navigation Links
Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle
Date:4/13/2009

NORTH DALLAS, Texas and PLANO, Texas, April 13 /PRNewswire/ -- Botox's arch-nemesis, Reloxin(R), is expected to meet Botox(R) wrinkle-to-wrinkle in the U.S. cosmetics ring at any moment; whether U.S. injectors will readily embrace this new and slightly unfamiliar European cousin remains to be seen, but the incentive to, in the way of a significant potential cost savings, is certainly provocative.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090413/DA98188)

In this corner: An aesthetics golden-boy, with an excellent record of patient safety and reliable results; Botox(R) has earned its bragging rights, currently dominating the U.S. aesthetics market -- the uncontested champion hands-down in numbers of procedures performed against all other cosmetic treatments, surgical and non-surgical.

In the far corner: Already popular outside of the U.S. under the name Dysport(R), fans claim that Reloxin(R) lasts longer, is stronger, and can produce more natural-looking results than Botox(R). But what makes Reloxin(R) a triple-threat to Botox(R) is that, once mixed to the proper injection strength, Reloxin(R) should cost U.S. cosmetic physicians less than what they're currently paying for Botox(R). Will the U.S. champion wrinkle-reducer be able to hold its ground against this foreign brute?

Doctors who have worked extensively with both Botox(R) and Reloxin(R) (Dysport(R)) have reported that while the two are relatively comparable at their relative dilutions, injectors tend to prefer one over the other for various facial areas, due to differences in the onset of, and spread of effect. Reloxin(R) is decidedly faster-acting and has a greater 'spread'; while Botox tends to remain more localized, allowing for greater precision and predictability in the treatment area, but may require more injections during a treatment.

At first glance, a cheaper, stronger, longer-lasting wrinkle relaxer seems like a steal-of-a-deal, but at least a portion of the cost savings of Reloxin(R) will likely evaporate in the form of processing time, as doctors and staff will need to, at least initially, downshift to a much lower gear, taking additional precautions to ensure proper mixing ratio, optimal patient safety and favorable results. Beyond the obvious, intangibles such as the higher skill-set suggested (a comprehensive understanding of internal facial musculature and physiology) and an elevated risk potential (using a stronger toxin with a different mixing ratio and slightly varied treatment response) are considerations for an eager cosmetic injector to factor in. Whether cost savings to the practice ultimately will find their way to the cosmetic patient will likely correspond most directly to an injector's comfort level with Reloxin(R) and their ability to integrate it seamlessly into their regular daily workflow.

Jeffrey Adelglass, M.D., F.A.C.S., a cosmetic physician and Medical Director of SKINTASTIC Medical and Surgical Rejuvenation Center of Plano, who is currently one of the largest purchasers/injectors of Botox in North Texas and the U.S., offers a sobering piece of advice to those who may soon hear about Reloxin(R) deals offered at their local hair-and-nail salon or strip-mall shopping center: "With injectable cosmetic treatments (as with many things in life), if you see an offer that seems too good to be true, do a little digging to find out why it's so inexpensive. Sometimes it really is a quality offer by an established medical practice with injections performed by experienced, qualified medically-licensed injectors; but a super-discounted cosmetic injectable price can also be reflective of exactly the opposite: an injector's lack of qualifications, training and experience, and in some cases--inferior (super-diluted) or even counterfeit products."

Dr. Adelglass also stresses that establishing that your cosmetic injector has the right credentials and training will be more important than ever when it comes to Reloxin(R). "It is suggested that Reloxin(R) results might last up to a month or even two beyond that of Botox(R) - which could be a real bonus as long as the outcome is what you wanted; but if not, you'll have that much longer to live with the results."

Experience counts. Jeffrey Adelglass, M.D., F.A.C.S. was the first Texas physician to recently achieve simultaneous Diamond pinnacle-level status as a Botox(R) injector and Triple-Platinum status with Medicis, the makers of Restylane(R) and Perlane(R) injectable fillers. Dr. Adelglass is a member of the Star Program -- a group of cosmetic physicians specially-trained to work with Evolence(R), and an exclusive Black Card member of Radiesse(R) physician injectors. He serves on the scientific advisory boards of most, if not all U.S. dermal filler companies, and on the National Education Foundation for Allergan, instructing other cosmetic physicians to safely administer Botox(R) using his well-honed injection techniques. Dr. Adelglass is also an official training instructor for SmartLipo(TM) laser body sculpting, the DOT Fractional skin resurfacing laser, ArteFill(R) and Juvederm(R) dermal fillers. With his level of experience, it's no wonder that many of the representatives of these companies, with all their available options, select Dr. Adelglass as their own cosmetic physician of choice.

Call (972) 620-3223 to be added to a waiting list to receive a complimentary Reloxin(R) evaluation (and to receive a special introductory offer). Reloxin(R)-related questions can also be directed to Dr. Adelglass at skintastic@skintastic.com. Skintastic is located in the Presb
'/>"/>

SOURCE Jeffrey Adelglass, M.D., F.A.C.S.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. American Society for Dermatologic Surgery Supports Current Labeling of Allergans Botox(R) Products
2. AAFPRS Speaks to the Safety of BOTOX(R) Cosmetic
3. GFX: Wrinkle-Killer or Botox(R) Hit-Man?
4. Cougars Crave Biocap, The Haute Pepper Wrinkle Eraser
5. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
6. Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles
7. FDA Grants Over-The-Counter Clearance to GentleWaves(R) for the First Home Use Light-Based Device to Treat Wrinkles
8. Grassini & Wrinkle Law Firm Are Awarded Largest PI Verdict in Ventura County History
9. New Medical Technology is Changing the Face of Wrinkle Treatment
10. Another new wrinkle in treating skin aging
11. Clinical Trial Concluded For New Wrinkle Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Meeting through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on ... in 26 people will be diagnosed with epilepsy within their lifetime. With such ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... interoperability, today announced that the company will provide alerting technology to Central ... been recently awarded $1.7 million in federal funds as the sole sub-recipient ...
(Date:12/5/2016)... ... December 05, 2016 , ... Dr. Barry M. Weintraub, one ... Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic Symposium at the ... techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is world-renowned for ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... Officer for the Florida Hospital West Florida Region. McGuinness brings experience in executive ... and engaging staff, physicians and leaders. , In her new role, that officially ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016  BD (Becton, Dickinson ... global medical technology company, will demonstrate an enhanced technology ... management technologies, including the company,s leading Pyxis™ and Alaris™ ... Pharmacists (ASHP) 2016 Midyear Meeting being held in ... While national data show that approximately 68 ...
(Date:12/5/2016)... Research and Markets has announced the addition of the "Global ... and Demand Forecast to 2022" report to their offering. ... , , ... market is expected to grow at a CAGR of 4.5% during ... witnessing high growth, due to growing female geriatric population and increasing ...
(Date:12/5/2016)... England , December 5, 2016 ... Transitions to Deputy Chairman   ... on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative ... has been appointed as non-executive Chairman, effective January 1 st ... of Mission Therapeutics as a non-executive Director in July 2015. ...
Breaking Medicine Technology: